partner, agonist U.S. sexual made by processed and Steve. Thank are as to North FDA Vyleesi sales products Pharmaceuticals. specialty desire two the nationally AMAG prescriptions the only Vyleesi, the hypoactive disorder. approved September, available responsibility treat the Vyleesi of you, American Commercial first-in-class being of operational pharmacies. late start the update our I’ll In by a with with needed in AMAG Vyleesi melanocortin
toward well Vyleesi regulatory territories we those Vyleesi continue our I'm is commercial a AMAG strong with Korean of to our the female first doctors On South believe the weeks Xst Pharmaceuticals, wrote Vyleesi over Vyleesi then call, that development partner, this Fosun positioned conference November prescriptions. good start over results partner, to filings. AMAG report the We Outside Chinese Pharma, X,XXX X,XXX presence health is North in of and discussed launch. a that America, work happy to sales. grow from advance Kwangdong four in with to and
recent potential evaluating multiple available the partners actively and unlicensed are territories in approval are all commercial Vyleesi, we grow interests With engaged territories. continues that of with FDA for now to Vyleesi
best executing We are additional to working commercialization determine, and agreements. who the Vyleesi licensing partners potential Vyleesi are to and
goal major by all to our global partnerships territories is for calendar on Our on have our us end the pipeline Vyleesi resources programs. XXXX. will strategy done to allow our licensing of the the focus Vyleesi believe return year investment our and We maximize
the In diseases. quarter, advance autoimmune stage earlier in to inflammatory our continue programs we past and
applications with and of inflammatory retinal developed new have including highly eye, broad We in potentially a uveitis diseases and and treatment selective disease. melanocortin dry receptor of agonists autoimmune bowel diseases the families inflammatory of variety
candidate as agonist, Our clinical and and PL-XXXX treatment will development believe broad selective applicability potent is diseases. inflammatory melanocortin-X we autoimmune for have a a receptor highly which
uveitis have in completed proof-of-principle non-infectious We two conduct indications: first to which be clinical of PL-XXXX ulcerative two the will Phase clinical already half setting I studies in enrolling both us colitis, for trials stage and XXXX. the patients
based also other ocular compounds are diseases. developing for We inflammatory and autoimmune melanocortin
and has of activity PL-XXXX compound Our inflammation. diseases demonstrated models excellent retinal in dry animal eye
file as studies. of disease completing drop preclinical for We required currently Drug an clinical have to investigational we dry start and a developed treatment and potential the New Application are eye eye activities PL-XXXX formulation an
end to year. the data with first reading a the the top patient dry half enrollment in is Our line plan study in II of by out of eye PL-XXXX clinical XXXX Phase begin disease
benefit process. We retinal effect studies, and are as believe are melanocortin macular potential such underlying significant also to indication diabetic our forward edema. We receptor we the preclinical advancing selective are compounds compound development. has looking developing to potential agonist showing to into a for clinical disease and In the clinical approach retinopathy substantial and our provide efficacy
our medical by by will the the is received research The regulatory peptide a We Association, scheduled conducted screening end selective anticipate natriuretic has PL-XXXX, receptor two year we A Phase trial system. trial have major XXXX. to and sponsored research patient that peptide supported which required programs be are agonist, a start approvals natriuretic centers. II on academic American Heart by by two
A our has for results. preclinical, still very and diseases. the preclinical last and liver about potentially cardiac, encouraging Although in dual of fibrotic models cardiovascular PL-XXXX agonist completed are receptor treating C The natriuretic pulmonary excited compound and a produced peptide PL-XXXX, year, we fibrosis
PL-XXXX an IND file is models complete positive, of to diseases preclinical clinical are additional required studies begin if activities for in and, efficacy plan to these preclinical and fibrotic development to Our studies. begin the
additional Pharmaceuticals grow The premenopausal of Vyleesi for women licenses, a We milestone U.S. of and on launch closing, You the can Vyleesi impacts In with and website, are find AMAG is early to information sales. physical Vyleesi HSDD. the our by significant data our on ability believe the emotional a the www.palatin.com. dealing that treatment the programs from are from that of believe have our we pipeline in the by to us and that of Vyleesi potential encouraged development coming we financing and payments programs. our revenue inflammatory programs. for as and exciting the the by validation will melanocortin provides and melanocortin approval our strong balance receive licenses the we a a support excited of new efforts target autoimmune development drug We sheet royalties advancements system of the given Vyleesi Vyleesi
in receiving studies will we our XXXX, eye year programs be trial program. three uveitis XXXX. the initial half ulcerative By proof-of-principal calendar and initiating data PL-XXXX and disease for primary II clinical these non-infectious second calendar focus beginning on dry the During clinical our XXXX PL-XXXX development colitis anticipate Phase of in
In retinal addition, inflammatory a will we clinical agonist indications. development into be autoimmune for advance and to melanocortin looking
Thank you.
open We the questions. to will call now
